Pharmaceutical Benefits Advisory Committee review of pneumococcal vaccines on the National Immunisation Program for older adults


Advocacy Reports and submissions 2019 reports and submissions Pharmaceutical Benefits Advisory Committee review of pneumococcal vaccines on the National Immunisat

Summary

Date: 27 June 2019

The RACGP provided input on the recent PBAC review of pneumococcal vaccines in older adults. Emphasis was placed on the importance of a sound evidence-base for the removal of any vaccine from the NIP.

The RACGP response covers the following:

  1. Vaccine effectiveness and cost effectiveness against invasive pneumococcal disease and community-acquired pneumonia
  2. The impact of removing a vaccine from the National Immunisation Program.